Compare AbbVie Inc (ABBV) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Celsius Holdings, Inc. — how do they compare? AbbVie Inc trades at $253.82 (market cap $449.91B), while Celsius Holdings, Inc. trades at $30.53 (market cap $8.10B). The key difference: AbbVie Inc is far larger — about 55.5× Celsius Holdings, Inc.'s market cap, and AbbVie Inc pays a 2.72% dividend while Celsius Holdings, Inc. pays none. Which is the better fit depends on your goals.
| ABBV | CELH | |
|---|---|---|
Market Cap | $449.91B | $8.10B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $64.86 |
52-Week Low | $184.85 | $27.75 |
Enterprise Value | $513.38B | $9.98B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
Celsius Holdings (CELH) trades at $31.70, down 4.4% on the day, with strong analyst consensus (95.65% buy ratings) and a $53.11 price target. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.41 beating expectations of $0.29. Revenue growth is robust, projected at $3.0B for 2026, though net margins have compressed from 17.2% in 2023 to 4.29% in 2025. Technical indicators show a bullish moving average trend but neutral oscillators, with key resistance at $34.
The outlook remains positive driven by international expansion and functional beverage demand, but risks include margin pressure, ongoing legal investigations, and high valuation multiples. The stock offers significant upside to consensus targets if growth execution continues, though investor sentiment is tempered by near-term profitability concerns and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
